Friday, January 03, 2025 11:26:08 AM
Sure, but what does that tell you about their confidence in this lawsuit?
This is not Hikma's first rodeo. They get sued all the time. It is literally part of their business model. They have over 800 products they sell, do nearly $3B in revenue, have a market cap of $5.5B, and I doubt they are that worried about Amarin. If they were, they would have withdrawn from selling IPE.
And even if Amarin is somehow still around in 4 or 5 years, and happens to win the appeal of the appeal, they then have a protracted fight about the damages. And there will be extensive analysis of how to arrive at "lost profits" for Amarin. And this process will drag on for years.
Look at GSK vs. Teva. Very similar case. Filed in 2014, still ongoing to this day. They're actually talking about a potential new trial. https://casetext.com/case/glaxosmithkline-llc-v-teva-pharm-us-3 . Amarin's case was only filed in 2020. How much money do you think GSK has spent on this trial? And Teva? And do you think Hikma can outlast Amarin?
The company is going to be sold long before this lawsuit ever has any impact on Amarin. A final, post-appeal decision is at least 4 years away. The only thing happening right now is lawyers getting rich.
I know others see it differently, and that is fine. I'm more concerned with Amarin's actual operations, not in a lawsuit that will likely never amount to anything meaningful for Amarin.
This is not Hikma's first rodeo. They get sued all the time. It is literally part of their business model. They have over 800 products they sell, do nearly $3B in revenue, have a market cap of $5.5B, and I doubt they are that worried about Amarin. If they were, they would have withdrawn from selling IPE.
And even if Amarin is somehow still around in 4 or 5 years, and happens to win the appeal of the appeal, they then have a protracted fight about the damages. And there will be extensive analysis of how to arrive at "lost profits" for Amarin. And this process will drag on for years.
Look at GSK vs. Teva. Very similar case. Filed in 2014, still ongoing to this day. They're actually talking about a potential new trial. https://casetext.com/case/glaxosmithkline-llc-v-teva-pharm-us-3 . Amarin's case was only filed in 2020. How much money do you think GSK has spent on this trial? And Teva? And do you think Hikma can outlast Amarin?
The company is going to be sold long before this lawsuit ever has any impact on Amarin. A final, post-appeal decision is at least 4 years away. The only thing happening right now is lawyers getting rich.
I know others see it differently, and that is fine. I'm more concerned with Amarin's actual operations, not in a lawsuit that will likely never amount to anything meaningful for Amarin.
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
